A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.
Journal Article
Objective
The goal of this study was to assess the efficacy and tolerability of lis-dexamfetamine dimesylate (LDX) as an adjunct to nicotine replacement therapy in adult smokers with ADHD who were undergoing a quit attempt.Methods
Thirty-two regular adult smokers with ADHD were randomized to receive LDX (n = 17) or placebo (n = 15) in addition to nicotine patch concurrent with a quit attempt.Results
There were no differences between smokers assigned to LDX versus placebo in any smoking outcomes. Participants treated with LDX demonstrated significant reductions in self-reported and clinician-rated ADHD symptoms. LDX was well tolerated in smokers attempting to quit.Discussion
In general, LDX does not facilitate smoking cessation in adults with ADHD more than does placebo, though both groups significantly reduced smoking. LDX demonstrated efficacy for reducing ADHD symptoms in adult smokers engaging in a quit attempt.Full Text
Duke Authors
Cited Authors
- Kollins, SH; English, JS; Itchon-Ramos, N; Chrisman, AK; Dew, R; O'Brien, B; McClernon, FJ
Published Date
- February 2014
Published In
Volume / Issue
- 18 / 2
Start / End Page
- 158 - 168
PubMed ID
- 22508760
Pubmed Central ID
- 22508760
Electronic International Standard Serial Number (EISSN)
- 1557-1246
International Standard Serial Number (ISSN)
- 1087-0547
Digital Object Identifier (DOI)
- 10.1177/1087054712440320
Language
- eng